AML, Adult Clinical Trials

53 clinical trials for AML, Adult across international registries, including 21 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• MRD-positive AML Clinical Study — RECRUITING · NA
• Revumenib in Combination With 7+3 + Midostaurin in AML — RECRUITING · PHASE1
• Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients — RECRUITING · PHASE3
• Quality of Life-Guided Transfusion in Refractory MDS or AML — RECRUITING · NA
• OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia — RECRUITING
• Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML — RECRUITING · PHASE1
• Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial) — RECRUITING
• Venetoclax-Decitabine in Untreated Elderly/Unfit AML — RECRUITING · NA
• Assessment of Geriatric Evaluations Impact on New AML Guidance — RECRUITING
• Pharmacoscopy-guided Clinical Standard-of-care in r/r AML — RECRUITING · PHASE2
• Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia — RECRUITING · PHASE2
• Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy — RECRUITING
• A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) — RECRUITING · PHASE1
• Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML — RECRUITING · PHASE1
• Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia — RECRUITING · PHASE1
• A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML — RECRUITING · PHASE2
• Novel Approaches to Target MECOM/EVI1 in AML — RECRUITING · NA
• A Study of Chidamide With AZA in MRD Positive AML After Transplant — RECRUITING · NA
• Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia — RECRUITING · PHASE1
• A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia — RECRUITING · PHASE2
• Precision Therapy Versus Standard Therapy in AML and MDS in Elderly — RECRUITING · PHASE2
• Quality of Life Model for Older Patients With AML — ACTIVE_NOT_RECRUITING
• Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS — ACTIVE_NOT_RECRUITING · NA
• VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML — NOT_YET_RECRUITING · PHASE3
• A Study of BN104 in the Treatment of Acute Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia — COMPLETED · PHASE1
• Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia — COMPLETED · PHASE1
• Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia — NOT_YET_RECRUITING · NA
• Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT — NOT_YET_RECRUITING · PHASE2
• Avapritinib Maintenance for AML With KIT Mutations — NOT_YET_RECRUITING · PHASE2
• NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS — ACTIVE_NOT_RECRUITING · PHASE1
• Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia — COMPLETED · PHASE1
• A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) — TERMINATED · PHASE1
• Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia — TERMINATED · PHASE1
• Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML — ACTIVE_NOT_RECRUITING · PHASE3
• A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS — TERMINATED · PHASE1
• Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine — OTHER
• IL-6: A Marker for AML Chemo Sensitivity — OTHER
• Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR — NOT_YET_RECRUITING · PHASE3
• Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax — NOT_YET_RECRUITING · NA
• D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid Leukemia — OTHER
• A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) — OTHER · PHASE1
• FT538 in Subjects With Advanced Hematologic Malignancies — TERMINATED · PHASE1
• Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib — TERMINATED · PHASE1
• A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML — OTHER · PHASE1
• Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS — OTHER · PHASE2
• Natural Killer(NK) Cell Therapy in r/r AML — OTHER · PHASE1
• Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia — OTHER · PHASE1
• HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt. — TERMINATED · PHASE1
• Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia. — TERMINATED · PHASE2

Refine this search